|
|
Superiority
of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and
vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson
CB
Department of Neurological Surgery, University of California-San Francisco
Medical School 94143
Data from Northern California Oncology Group protocol 6G61, which was closed in
February 1983, were reanalyzed in December 1988.
The protocol called for a
randomized trial that compared the effects of following 60 Gy radiation/oral
hydroxyurea treatment with either carmustine (BCNU) or the combination of
procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata:
glioblastoma multiforme and other anaplastic gliomas.
PCV produced longer
survival and time to tumor progression than BCNU for both histologic groups,
although the difference was statistically significant only for the anaplastic
gliomas.
With PCV treatment, time to progression and survival doubled for
anaplastic glioma patients in the 50th and 25th percentiles.
PMID: 2154418 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2154418&dopt=Abstract |
